Abstract
Background Understanding the risk of chikungunya virus (CHIKV) infection and rheumatic sequelae across populations, including travelers and the military, is critical. We leveraged the electronic medical records of about 9.5 million U.S. Military Health System (MHS) beneficiaries to identify the risk of post-CHIKV rheumatic sequelae.
Methodology/Principal Findings MHS beneficiary CHIKV infections diagnosed 2014–2018 were identified from the Disease Reporting System internet, TRICARE Encounter Data Non-Institutional, and Comprehensive Ambulatory/Professional Encounter Record systems. Non-CHIKV controls were matched (1:4) by age, gender, beneficiary status, and encounter date. The frequency of comorbidities and incident rheumatic diagnoses through 2020 were derived from International Classification of Diseases codes and compared between cases and controls. Logistic regression models estimated the association of CHIKV infection with rheumatic sequelae and risk factors for post-CHIKV sequelae. 195 CHIKV cases were diagnosed between July 2014 and December 2018. The mean age was 42 years, and 43.6% were active duty. 63/195 (32.3%) of CHIKV cases had an incident rheumatic diagnosis, including arthralgia, polyarthritis, polymyalgia rheumatica, and/or rheumatoid arthritis, compared to 156/780 (20.0%) of controls (p < 0.001). CHIKV infection remained associated with rheumatic sequelae (aOR = 1.911, p = 0.002) after adjusting for prior rheumatic disease and demography. Those with rheumatic CHIKV sequelae had a median 7 healthcare encounters (IQR 3–15). Among CHIKV infections, we found no association between post-CHIKV rheumatic sequelae and demography, service characteristics, or comorbidities.
Conclusions/Significance CHIKV infection is uncommon but associated with rheumatic sequelae among MHS beneficiaries, with substantial healthcare requirements in a proportion of cases with such sequelae. No demographic, clinical, or occupational variables were associated with post-CHIKV rheumatic sequelae, suggesting that prediction of these complications is challenging in MHS beneficiaries. These findings are important context for future CHIKV vaccine decision making in this and other populations.
Author summary We examined U.S. Military Health System (MHS) electronic medical records during to identify the likelihood of rheumatic complications after chikungunya virus (CHIKV) infection. Overall, CHIKV infections were rare in the MHS, with 195 cases found in the records between 2014 and 2018 (a period which encompassed the peak of the CHIKV epidemic in the Americas). Of these, about 32% received a rheumatic diagnosis after infection, including arthralgia, polyarthritis, polymyalgia rheumatica, and rheumatoid arthritis. Patients who had a rheumatic diagnosis had on average 7 healthcare encounters for their post-CHIKV rheumatic complication, and a quarter had more than 15 healthcare encounters. We did not find any demographic, clinical, or occupational characteristics associated with developing rheumatic complications after CHIKV, suggesting that predicting rheumatic complications from CHIKV may be challenging in MHS beneficiaries. These findings may provide important context for decisions about implementing an approved chikungunya vaccine to military servicemembers and other MHS beneficiaries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The protocol was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense program executed by the Uniformed Services University of the Health Sciences through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.. This project has been funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, under an interagency agreement (Y1-AI-5072); and the Military Infectious Diseases Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol was reviewed and approved for execution by the IRB of the Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data for this study are available from the Infectious Disease Clinical Research Program (IDCRP), headquartered at the Uniformed Services University of the Health Sciences (USU), Department of Preventive Medicine and Biostatistics. Review by the USU Institutional Review Board is required for use of the data used in this protocol. Furthermore, the data set includes Military Health System data collected under a Data Use Agreement that requires accounting for uses of the data. Data requests may be sent to: Address: 6270A Rockledge Drive, Suite 250, Bethesda, MD 20817. Email: contactus{at}idcrp.org
